HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inverness Expands Home Pregnancy Market Share With Fact Plus Acquisition

This article was originally published in The Tan Sheet

Executive Summary

Inverness Medical Innovations will immediately take over distribution of Abbott Labs' Fact plus OTC home pregnancy tests after acquiring the line along with several professional test kit products from the firm in a $92.5 mil. deal

You may also be interested in...



Inverness results

FY 2003 net revenues jumped 42.5% to $296.4 mil., while fourth quarter net sales rose to $93.5 mil. from $65.1 mil in prior-year period, Inverness announces Feb. 18. The increases are primarily attributable to acquired businesses, the June launch of ClearBlue digital pregnancy test and the acquisition of Abbott Labs test kit lines, including Fact plus home pregnancy tests, Waltham, Mass.-based firm says. Inverness acquired products in September (1"The Tan Sheet" Oct. 6, 2003, p. 13)...

Pfizer, Inverness Agree To Work Together On Digital e.p.t. Pregnancy Test

Pfizer will soon sell a digital version of its e.p.t. pregnancy test kit after Inverness Medical Innovations consents to let the firm's Warner-Lambert subsidiary use Inverness' patented technology employed in its Clearblue Easy Digital product

Inverness

Clearblue pregnancy test line sales are up 60% since the June launch of the digital line extension, helping Inverness Medical Innovations revenues grow 34% to $72.4 mil. in the third quarter ended Sept. 30, CEO Ron Zwanziger reports during Nov. 5 earnings call. While "it is too early to call [Clearblue digital] a success, it does seem to be moving rather well," Zwanziger says. Inverness' net income totaled $1.7 mil. versus $1.1 mil. in the prior-year period. Zwanziger forecasts the company will achieve between $85 mil. and $90 mil. in Q4 sales. However, he cautioned that a one-time, $1.2 mil. "bump" in Q4 R&D spending and the negative impact of costs associated with integration of the Fact plus, TestPack and Signify lines of rapid diagnostic tests for pregnancy, strep throat and drug abuse, which Inverness recently acquired from Abbott Labs, will dampen overall sales growth slightly (1"The Tan Sheet" Oct. 6, 2003, p. 13)...

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel